vs
Side-by-side financial comparison of BIOHARVEST SCIENCES INC. (BHST) and Foghorn Therapeutics Inc. (FHTX). Click either name above to swap in a different company.
Foghorn Therapeutics Inc. is the larger business by last-quarter revenue ($9.2M vs $8.4M, roughly 1.1× BIOHARVEST SCIENCES INC.).
BioHarvest Sciences Inc. is a biotechnology firm that develops and produces sustainable, high-purity plant-derived bioactive ingredients. It serves the nutraceutical, cosmetics, and pharmaceutical sectors, leveraging proprietary cell cultivation technology to create efficacious natural products without large-scale agricultural farming.
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies targeting the chromatin regulatory system to treat various types of cancer and other severe diseases. It advances a diverse pipeline of targeted drug candidates, conducting internal R&D and strategic partnerships to serve global patient populations.
BHST vs FHTX — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $8.4M | $9.2M |
| Net Profit | — | $-21.7M |
| Gross Margin | 60.3% | — |
| Operating Margin | — | -258.2% |
| Net Margin | — | -234.3% |
| Revenue YoY | — | 223.8% |
| Net Profit YoY | — | -11.1% |
| EPS (diluted) | — | $-0.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $9.2M | ||
| Q3 25 | $8.4M | $8.2M | ||
| Q2 25 | $8.1M | $7.6M | ||
| Q1 25 | $7.7M | $6.0M | ||
| Q4 24 | — | $2.9M | ||
| Q3 24 | $6.5M | $7.8M | ||
| Q2 24 | $6.0M | $6.9M | ||
| Q1 24 | — | $5.0M |
| Q4 25 | — | $-21.7M | ||
| Q3 25 | — | $-15.8M | ||
| Q2 25 | — | $-17.9M | ||
| Q1 25 | — | $-18.8M | ||
| Q4 24 | — | $-19.5M | ||
| Q3 24 | — | $-19.1M | ||
| Q2 24 | — | $-23.0M | ||
| Q1 24 | — | $-25.0M |
| Q4 25 | — | — | ||
| Q3 25 | 60.3% | — | ||
| Q2 25 | 60.0% | — | ||
| Q1 25 | 58.2% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -258.2% | ||
| Q3 25 | — | -226.9% | ||
| Q2 25 | — | -279.2% | ||
| Q1 25 | — | -385.0% | ||
| Q4 24 | — | -840.5% | ||
| Q3 24 | — | -305.5% | ||
| Q2 24 | — | -386.6% | ||
| Q1 24 | — | -558.3% |
| Q4 25 | — | -234.3% | ||
| Q3 25 | — | -194.4% | ||
| Q2 25 | — | -237.3% | ||
| Q1 25 | — | -316.4% | ||
| Q4 24 | — | -682.9% | ||
| Q3 24 | — | -244.9% | ||
| Q2 24 | — | -333.6% | ||
| Q1 24 | — | -495.4% |
| Q4 25 | — | $-0.35 | ||
| Q3 25 | — | $-0.25 | ||
| Q2 25 | — | $-0.28 | ||
| Q1 25 | — | $-0.30 | ||
| Q4 24 | — | $-0.23 | ||
| Q3 24 | — | $-0.31 | ||
| Q2 24 | — | $-0.45 | ||
| Q1 24 | — | $-0.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $80.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $-108.5M |
| Total Assets | — | $198.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $80.9M | ||
| Q3 25 | — | $89.3M | ||
| Q2 25 | — | $72.6M | ||
| Q1 25 | — | $61.0M | ||
| Q4 24 | — | $55.5M | ||
| Q3 24 | — | $57.7M | ||
| Q2 24 | — | $138.9M | ||
| Q1 24 | — | $79.3M |
| Q4 25 | — | $-108.5M | ||
| Q3 25 | — | $-89.7M | ||
| Q2 25 | — | $-76.7M | ||
| Q1 25 | — | $-61.7M | ||
| Q4 24 | — | $-45.5M | ||
| Q3 24 | — | $-28.3M | ||
| Q2 24 | — | $-14.3M | ||
| Q1 24 | — | $-97.5M |
| Q4 25 | — | $198.1M | ||
| Q3 25 | — | $205.0M | ||
| Q2 25 | — | $226.2M | ||
| Q1 25 | — | $258.7M | ||
| Q4 24 | — | $284.0M | ||
| Q3 24 | — | $308.4M | ||
| Q2 24 | — | $328.6M | ||
| Q1 24 | — | $255.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-22.3M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-22.3M | ||
| Q3 25 | — | $-18.9M | ||
| Q2 25 | — | $-21.0M | ||
| Q1 25 | — | $-24.0M | ||
| Q4 24 | — | $-24.5M | ||
| Q3 24 | — | $-21.0M | ||
| Q2 24 | — | $-25.5M | ||
| Q1 24 | — | $-29.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-21.0M | ||
| Q1 25 | — | $-24.0M | ||
| Q4 24 | — | $-25.0M | ||
| Q3 24 | — | $-21.3M | ||
| Q2 24 | — | $-25.6M | ||
| Q1 24 | — | $-29.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -278.2% | ||
| Q1 25 | — | -403.2% | ||
| Q4 24 | — | -875.3% | ||
| Q3 24 | — | -273.0% | ||
| Q2 24 | — | -371.0% | ||
| Q1 24 | — | -583.1% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 0.5% | ||
| Q4 24 | — | 16.8% | ||
| Q3 24 | — | 4.0% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 2.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
